Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Archives of Neurology|November 16, 2011
Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-upCarmen Tur, Xavier Montalban, Mar Tintoré, et al.
Clinical Immunology (Orlando, Fla.)|October 24, 2008
Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosisManuel Comabella, Jordi Río, Carmen Espejo, et al.
Annals of Clinical and Translational Neurology|October 24, 2018
Variably protease-sensitive prionopathy presenting within ALS/FTD spectrumMikel Vicente-Pascual, Marcello Rossi, Josep Gámez, et al.
Prion|September 20, 2013
PrP mRNA and protein expression in brain and PrP(c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2Franc Llorens, Belén Ansoleaga, Paula Garcia-Esparcia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 16, 2013
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changesAngela Vidal-Jordana, Jaume Sastre-Garriga, Francisco Pérez-Miralles, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2017
Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patientsJordi Río, Àlex Rovira, Mar Tintoré, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 3, 2012
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decisionCarmen Tur, Mar Tintoré, Angela Vidal-Jordana, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2015
Should we systematically test patients with clinically isolated syndrome for auto-antibodies?Laura Negrotto, Carmen Tur, Mar Tintoré, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2021
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of CataloniaLuciana Midaglia, Jaume Sastre-Garriga, Agustín Pappolla, et al.
Plos One|December 17, 2013
Risk acceptance in multiple sclerosis patients on natalizumab treatmentCarmen Tur, Mar Tintoré, Ángela Vidal-Jordana, et al.
Pageof 7